摘要
目的分析国家“4+7”带量采购政策在杭州某医院的实施效果及对该院相关品类口服降糖药物使用的影响,并探讨由此带来的经验和启示。方法采用药物经济学方法对“4+7”带量采购政策实施后6个月与2019年同期6个月门诊口服降糖药的单价、使用数量、使用金额及日均费用(DDC)进行分析。结果实施“4+7”带量采购政策后,相关药品各大厂家联动降价,阿卡波糖单价最高降幅64.47%,格列美脲单价降幅达18.65%。阿卡波糖在品类中使用量比例较为稳定,但使用金额比例显著下降,由90.54%大幅下降至52.17%,DDC值由8.70元/d降至2.42元/d,较前下降6.28元/d;格列美脲使用量比例由24.91%下降至11.46%,使用金额比例由原来的38.29%降至0.53%,DDC值下降4.20元/d。结论本次“4+7”带量采购政策实施对相关品类口服降糖药的使用呈现不同影响,但相关药物使用的日均费用均大幅下降,切实减轻了患者的用药负担,可为构建我国特色的药物价格动态调整机制提供参考。
Objective To analyze the implementation effect of the national“4+7”volume-based procurement policy in a hospital in Hangzhou and its effect on the use of related oral hypoglycemic drugs,and to explore the experience and enlightenment.Methods Pharmacoeconomics method was used to analyze the unit price,quantity used,amount used and defined daily cost(DDC)of oral hypoglycemic drugs in outpatients 6 months after the implementation of the“4+7”volume-based procurement policy and 6 months in the same period in 2019.Results After the implementation of the“4+7”volume-based procurement policy,the major manufacturers of related drugs jointly reduced the price.The unit price of acarbose decreased maximumly by 64.47%,and the unit price of glimepiride decreased by 18.65%.The proportion of acarbose used in the category was relatively stable,but the proportion of the amount used decreased significantly,from 90.54%to 52.17%,and the value of DDC decreased from 8.70 yuan/d to 2.42 yuan/d,which decreased by 6.28 yuan/d.The proportion of glimepiride used decreased from 24.91%to 11.46%,the proportion of amount used decreased from 38.29%to 0.53%,and the value of DDC decreased by 4.20 yuan/d.Conclusion The implementation of the“4+7”volume-based procurement policy exerts different effects on the use of related oral hypoglycemic drugs,but the DDC of related drugs has decreased significantly,which has effectively reduced the drug burden of patients and it can provide a reference for the construction of a dynamic adjustment mechanism of drug price with Chinese characteristics.
作者
杨惠卿
许志连
洪顺福
何飞燕
郑颖
YANG Huiqing;XU Zhilian;HONG Shunfu;HE Feiyan;ZHENG Ying(Department of Pharmacy,Hangzhou Hospital of Traditional Chinese Medicine,Hangzhou 310012,China)
出处
《中国现代医生》
2021年第33期154-157,共4页
China Modern Doctor
基金
浙江省医药卫生科技计划项目(2018PY036)。
